Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185933 | 1.00 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4185937 | 1.00 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL25435936 | 0.96 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL11315619 | 0.89 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL11302178 | 0.89 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL15519785 | 0.88 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL11177231 | 0.88 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9592045 | 0.87 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9188557 | 0.85 | CA1 (0.66) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9187215 | 0.85 | CA1 (0.66) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435379-B2 | [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190106393-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-04-11 | — | — | US | disclosed |
| US-10189796-B2 | [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180244633-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-08-30 | — | — | US | disclosed |
| EP-3342768-A1 | [4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | Santen Pharmaceutical Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-5530143-A | REDUCTION OF (3S)-3-HYDROXYOCTANEDIOIC DIESTER WITH COMPLEX HYDRIDE | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0487986-B1 | Process for the preparation of esters of (6s)-6,8-dihydroxyoctanoic acid | BASF AG (DE) | 1995-06-21 | — | — | EP | disclosed |
| EP-0487986-A2 | Process for the preparation of esters of (6s)-6,8-dihydroxyoctanoic acid | BASF Aktiengesellschaft (DE) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189796-B2 | [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | NR3C2, NR3C1, GRK4 | CA1 3560/4885CA2 1297/4885CA7 2140/4885 |
| US-10435379-B2 | [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | NR3C2, NR3C1, MC2R | CA1 2185/4885CA2 981/4885CA7 1418/4885 |
| US-20190106393-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | NR3C2, NR3C1, MC2R | CA1 2185/4885CA2 981/4885CA7 1418/4885 |
| US-20180244633-A1 | [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF | NR3C2, NR3C1, GRK4 | CA1 3560/4885CA2 1297/4885CA7 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.